Translations:Angiotensin II receptor blocker/33/ja: Difference between revisions

From Azupedia
Jump to navigation Jump to search
VisualWikitext
Created page with "|- | バルサルタン | Diovan | 6 | 2–4H | 95% | 25% | 30/70% | Yes | 80–320 | 基質: MRP2とOATP1B1/SLCO1B1 |- | イルベサルタン | Avapro | 11–15 | 1.5–2H | 90–95% | 70% | 20/80% | No | 150–300 | CYP2C9のマイナー基質 |- | テルミサルタン | Micardis | 24 | 0.5–1H | >99% | 42–58% | 1/99% | No | 40–80 |..."
 
(No difference)

Latest revision as of 08:56, 27 March 2024

Information about message (contribute)
This message has no documentation. If you know where or how this message is used, you can help other translators by adding documentation to this message.
Message definition (Angiotensin II receptor blocker)
|-
| [[Valsartan]]
| Diovan
| 6
| 2–4 hrs
| 95%
| 25%
| 30/70%
| Yes
| 80–320
| Substrates: [[Multidrug resistance-associated protein 2|MRP2]] and [[OATP1B1|OATP1B1/SLCO1B1]]
|-
| [[Irbesartan]]
| Avapro
| 11–15
| 1.5–2 hrs
| 90–95%
| 70%
| 20/80%
| No
| 150–300
| Minor substrates of [[CYP2C9]]
|-
| [[Telmisartan]]
| Micardis
| 24
| 0.5–1 hr 
| >99%
| 42–58%
| 1/99%
| No
| 40–80
| None known; >97% via biliary excretion
|-
| [[Eprosartan]]
| Teveten
| 5
| 1–2 hrs 
| 98%
| 13%
| 30/70%
| No
| 400–800
| None known; >90% via renal and biliary excretion
|-
| [[Olmesartan]]
| Benicar/Olmetec
| 14–16
| 1–2 hrs 
| >99%
| 29%
| 40/60%
| No
| 10–40
| Substrates of [[OATP1B1|OATP1B1/SLCO1B1]]
|-
| [[Azilsartan]]
| Edarbi
| 11
| 1.5–3 hrs 
| >99%
| 60%
| 55/42%
| No
| 40–80
| Minor substrates of CYP2C9 
|-
| [[Fimasartan]]
| Kanarb
| 7–11
| 0.5–3 hrs after dosing.
| >97%
| 30–40%
| –
| –
| 30–120
| None known; primarily biliary excretion 
|-
! Drug
! Trade name
! [[Biological half-life]] [hrs]
! [[Cmax_(pharmacology)|Peak plasma concentration [Tmax] ]]
! [[Protein binding]] [%]
! [[Bioavailability]] [%]
! Renal/hepatic [[Clearance (medicine)|clearance]] [%]
! Food effect
! Daily dosage [mg]
! [[Metabolism]]/[[Transport protein|transporter]]
|}

|- | バルサルタン | Diovan | 6 | 2–4H | 95% | 25% | 30/70% | Yes | 80–320 | 基質: MRP2とOATP1B1/SLCO1B1 |- | イルベサルタン | Avapro | 11–15 | 1.5–2H | 90–95% | 70% | 20/80% | No | 150–300 | CYP2C9のマイナー基質 |- | テルミサルタン | Micardis | 24 | 0.5–1H | >99% | 42–58% | 1/99% | No | 40–80 | 不明; >97% 胆汁排泄 |- | エプロサルタン | Teveten | 5 | 1–2H | 98% | 13% | 30/70% | No | 400–800 | 不明; >90% 腎と胆汁排泄 |- | オルメサルタン | Benicar/Olmetec | 14–16 | 1–2H | >99% | 29% | 40/60% | No | 10–40 | OATP1B1/SLCO1B1の基質 |- | アジルサルタン | Edarbi | 11 | 1.5–3H | >99% | 60% | 55/42% | No | 40–80 | CYP2C9のマイナー基質 |- | フィマサルタン | Kanarb | 7–11 | 服用後0.5–3H | >97% | 30–40% | – | – | 30–120 | 不明; 主に胆汁性排泄 |- ! 薬剤 ! 製品名 ! 半減期 [時間] ! ピーク血漿中濃度[Tmax] ! タンパク質結合率 [%] ! 生物学的利用能 [%] ! 腎／肝クリアランス [%] ! 食べ物の影響 ! 容量/日 [mg] ! 代謝/トランスポーター |}

Retrieved from "https://wiki.tiffa.net/w/index.php?title=Translations:Angiotensin_II_receptor_blocker/33/ja&oldid=131362"